|
Carcinogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Colorectal tumorigenesis is ascribed to the activity of Wnt signaling pathway in a ligand-independent manner mainly through APC and CTNNB1 gene mutations and in a ligand-dependent manner through low expression of Wnt inhibitors such as WNT inhibitory factor 1 (WIF1) and secreted frizzled related protein 1 (SFRP1).
|
24949429 |
2014 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In this article, we review the structure, evolution, molecular interactions and functions of WIF1 with major emphasis on its role in carcinogenesis.
|
31210071 |
2019 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To our knowledge, this is the first report suggesting that WIF1 is a recurrent target in human salivary gland oncogenesis and that downregulation of WIF1 plays a role in the development and/or progression of pleomorphic adenomas.
|
17171686 |
2007 |
|
Carcinogenesis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus.
|
18005197 |
2008 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Wnt inhibitory factor-1: a candidate for a new player in tumorigenesis of intestinal epithelial cells.
|
15019166 |
2004 |
|
Carcinogenesis
|
0.100 |
PosttranslationalModification
|
phenotype |
BEFREE |
WNT inhibitory factor 1 promoter hypermethylation is an early event during gallbladder cancer tumorigenesis that predicts poor survival.
|
28438695 |
2017 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Thus, the results demonstrated that WIF1 is frequently downregulated or silenced by promoter methylation in the carcinogenesis of OSF, which serves as a potential epigenetic biomarker for the early detection of OSCC.
|
26352791 |
2015 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
WIF-1 is a negative regulator of the Wnt-signaling pathway that may have important implications for tumorigenesis.
|
20596629 |
2010 |
|
Carcinogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
No significant association between WIF-1 downregulation and clinicopathological characteristics was found, suggesting that downregulation of WIF-1 expression is an early event in carcinogenesis of these cancers.
|
16007117 |
2005 |
|
Carcinogenesis
|
0.100 |
PosttranslationalModification
|
phenotype |
BEFREE |
Furthermore, while for both SFRP-1 and WIF-1 methylation-associated silencing occurred across the whole spectrum of colorectal tumorigenesis, DKK-1 promoter was selectively hypermethylated in advanced colorectal neoplasms (Duke's C and D tumors).
|
16491118 |
2006 |
|
Carcinogenesis
|
0.100 |
PosttranslationalModification
|
phenotype |
BEFREE |
Our data reveal that WIF1 downregulation occurs due to promoter hypermethylation and is an early event in cervical oncogenesis.
|
22002305 |
2012 |
|
Carcinogenesis
|
0.100 |
PosttranslationalModification
|
phenotype |
BEFREE |
Promoter hypermethylation of WIF-1 may play a crucial role in lung cancer carcinogenesis.
|
27930522 |
2016 |
|
Carcinogenesis
|
0.100 |
PosttranslationalModification
|
phenotype |
BEFREE |
These findings demonstrated that WIF1 silencing due to promoter hypermethylation is a major mechanism during carcinogenesis of ESCC.
|
23193918 |
2012 |
|
Carcinoma
|
0.040 |
GeneticVariation
|
group |
BEFREE |
We screened 13 additional benign and malignant salivary gland tumors and detected WIF1 rearrangement in one out of two carcinomas ex-pleomorphic adenoma analyzed.
|
17171686 |
2007 |
|
Carcinoma
|
0.040 |
PosttranslationalModification
|
group |
BEFREE |
Hypermethylation of WIF1 and RUNX3 genes promoters was observed in 35% and 25% of carcinomas, respectively.
|
21819494 |
2011 |
|
Carcinoma
|
0.040 |
PosttranslationalModification
|
group |
BEFREE |
The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas.
|
17384664 |
2007 |
|
Carcinoma
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Strong reduction of WIF1 protein expression was found in 23% of prostate carcinomas, but also in 60% of breast, 75% of non-small cell lung (NSCLC), and 26% of bladder cancers analysed.
|
14517837 |
2003 |
|
Carcinoma of bladder
|
0.040 |
Biomarker
|
disease |
BEFREE |
We hypothesize that Wif-1 plays an important role in bladder cancer pathogenesis.
|
16428476 |
2006 |
|
Carcinoma of bladder
|
0.040 |
Biomarker
|
disease |
BEFREE |
The increased methylation levels of WIF1 DNA CpG could be a potential biomarker for bladder cancer.
|
31322264 |
2019 |
|
Carcinoma of bladder
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer.
|
14517837 |
2003 |
|
Carcinoma of bladder
|
0.040 |
Biomarker
|
disease |
BEFREE |
These observations suggest a mechanism for transformation of bladder epithelium on loss of WIF1 function and provide new targets such as SKP2 for intervention in WIF1-deficient bladder cancer.
|
19174556 |
2009 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, we also showed that down-regulation of Wnt signaling by WIF-1 was required for bisdemethoxycurcumin-induced apoptosis in certain lung cancer cell types.
|
21933103 |
2011 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, there was no significant difference in WIF-1 gene methylation between tumor tissues among patients with lung cancer, gastric cancer, astrocytoma, and adjacent/normal tissues, indicating the WIF-1 gene methylation not a general nonspecific phenomenon.
|
29970693 |
2018 |
|
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
To discover the mechanism of WIF-1 silencing in lung cancer, we first identified the human WIF-1 promoter and subsequently examined the methylation status in the CpG islands.
|
15256437 |
2004 |
|
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The tumor suppressor gene Wnt inhibitory factor-1 (WIF-1) has been found to be promoter hypermethylated and silenced in lung cancer cell lines and tissues.
|
21484077 |
2011 |